Researchers found that a drug called Ampligen (rintatolimod) may offer complete protection against the Ebola virus when given early after infection. In a study conducted on mice, those treated with Ampligen showed a 100% survival rate, while untreated mice faced total mortality. This finding is particularly significant given the current Ebola outbreak in Central and East Africa, where there is no approved treatment or vaccine for the Bundibugyo strain of the virus.

For people concerned about health and longevity, the implications of this research are substantial. If Ampligen proves effective in humans, it could serve as a preventive measure or an early treatment option for Ebola virus disease. This would be especially valuable for healthcare workers and vulnerable populations who may be exposed to the virus. The study indicated that a dose of 6 mg/kg was effective in mice, and it has been well-tolerated in human trials at the same dosage.

The research is currently at the pre-clinical stage, meaning it has shown promising results in animal models but has not yet been proven in humans. While the findings are encouraging, more extensive human trials will be necessary to determine if Ampligen can effectively treat or prevent Ebola in people. The upcoming virtual presentation by AIM ImmunoTech will delve deeper into these findings and discuss potential pathways for further research.

Source: globenewswire.com